menu
    • menu
    [{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","amount":"$588.4 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","amount":"$588.4 million","upfrontCash":"Undisclosed","newsHeadline":"ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of Neuroendocrine Tumors at Annual ENETS Conference 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","amount":"$36.3 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Arginine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."}]

    Find Clinical Drug Pipeline Developments & Deals for Lysine

    Menu

    Lysine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmace...

                            Details : The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroe...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of N...

                            Details : ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma

                            Details : The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of N...

                            Details : ITM-11 (177Lu-edotreotide), a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors demonstrated promising results in its trial for the treatment of hard-to-treat tumors.

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 19, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater...

                            Details : Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and com...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 27, 2021

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4